Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S. Composition of Matter Patent Granted for Varoglutamstat

Core Viewpoint - Vivoryon Therapeutics N.V. has been granted a new U.S. patent for its lead drug varoglutamstat, enhancing its intellectual property portfolio and supporting its development strategy in kidney disease [2][3][7]. Group 1: Patent Details - The newly granted U.S. composition of matter patent (US 12,312,335) covers the only polymorph of the salt form used in varoglutamstat, with a patent term extending through 2044 and potential extension to 2049 under the Hatch-Waxman Act [3][4]. - The patent was granted after an accelerated examination process, indicating the efficiency and effectiveness of the company's patent application strategy [2][3]. Group 2: Strategic Focus - Vivoryon is actively pursuing additional patents related to varoglutamstat and its applications in kidney disease, including medical use and dosing regimens, both as monotherapy and in combination with SGLT-2 inhibitors [4][5]. - The company has filed multiple patents in the past months, reflecting its commitment to strengthening its intellectual property in the field of kidney diseases [4][5]. Group 3: Broader Patent Portfolio - Vivoryon has developed a robust patent portfolio for QPCT/L inhibitors, encompassing over 20 patent families and more than 400 patent applications and issued patents across major markets [6]. - The majority of the patents focus on composition of matter for QPCT/L inhibitors, with recent applications emphasizing the company's focus on kidney diseases and the synergistic effects observed in preclinical research [5][6].